A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

K. Berencsi, Z. Gyulai, E. Gönczöl, S. Pincus, W. I. Cox, S. Michelson, L. Kari, C. Meric, M. Cadoz, J. Zahradnik, S. Starr, S. Plotkin

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

The major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) is an important target of HLA-restricted cytotoxic T cells (CTL) after natural infection. A canarypox-CMV pp65 recombinant was studied for its ability to induce CMV pp65-specific CTL, helper T lymphocytes, and antibodies in a phase I clinical trial. Twenty-one CMV-seronegative adult volunteers were randomized to receive immunizations at months 0, 1, 3, and 6 with either canarypox-CMV pp65 or placebo. In canarypox-CMV pp65-immunized subjects, pp65-specific CTL were elicited after only 2 vaccinations and were present at months 12 and 26 in all subjects tested. Cell-depletion studies indicated that the CTL were phenotype CD8+. Peripheral blood mononuclear cells proliferated in response to stimulation with purified pp65, and antibodies specific for pp65 also were detected. Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV.

Original languageEnglish
Pages (from-to)1171-1179
Number of pages9
JournalJournal of Infectious Diseases
Volume183
Issue number8
DOIs
Publication statusPublished - Apr 15 2001

Fingerprint

Cytomegalovirus
T-Lymphocytes
Phosphoproteins
Clinical Trials, Phase I
Synthetic Vaccines
Antibodies
Helper-Inducer T-Lymphocytes
cytomegalovirus matrix protein 65kDa
Volunteers
Immunization
Blood Cells
Vaccination
Placebos
Phenotype
Infection

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. / Berencsi, K.; Gyulai, Z.; Gönczöl, E.; Pincus, S.; Cox, W. I.; Michelson, S.; Kari, L.; Meric, C.; Cadoz, M.; Zahradnik, J.; Starr, S.; Plotkin, S.

In: Journal of Infectious Diseases, Vol. 183, No. 8, 15.04.2001, p. 1171-1179.

Research output: Contribution to journalArticle

Berencsi, K, Gyulai, Z, Gönczöl, E, Pincus, S, Cox, WI, Michelson, S, Kari, L, Meric, C, Cadoz, M, Zahradnik, J, Starr, S & Plotkin, S 2001, 'A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects', Journal of Infectious Diseases, vol. 183, no. 8, pp. 1171-1179. https://doi.org/10.1086/319680
Berencsi, K. ; Gyulai, Z. ; Gönczöl, E. ; Pincus, S. ; Cox, W. I. ; Michelson, S. ; Kari, L. ; Meric, C. ; Cadoz, M. ; Zahradnik, J. ; Starr, S. ; Plotkin, S. / A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. In: Journal of Infectious Diseases. 2001 ; Vol. 183, No. 8. pp. 1171-1179.
@article{323fa31d48d44f75a6d09914ddac3731,
title = "A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects",
abstract = "The major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) is an important target of HLA-restricted cytotoxic T cells (CTL) after natural infection. A canarypox-CMV pp65 recombinant was studied for its ability to induce CMV pp65-specific CTL, helper T lymphocytes, and antibodies in a phase I clinical trial. Twenty-one CMV-seronegative adult volunteers were randomized to receive immunizations at months 0, 1, 3, and 6 with either canarypox-CMV pp65 or placebo. In canarypox-CMV pp65-immunized subjects, pp65-specific CTL were elicited after only 2 vaccinations and were present at months 12 and 26 in all subjects tested. Cell-depletion studies indicated that the CTL were phenotype CD8+. Peripheral blood mononuclear cells proliferated in response to stimulation with purified pp65, and antibodies specific for pp65 also were detected. Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV.",
author = "K. Berencsi and Z. Gyulai and E. G{\"o}ncz{\"o}l and S. Pincus and Cox, {W. I.} and S. Michelson and L. Kari and C. Meric and M. Cadoz and J. Zahradnik and S. Starr and S. Plotkin",
year = "2001",
month = "4",
day = "15",
doi = "10.1086/319680",
language = "English",
volume = "183",
pages = "1171--1179",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects

AU - Berencsi, K.

AU - Gyulai, Z.

AU - Gönczöl, E.

AU - Pincus, S.

AU - Cox, W. I.

AU - Michelson, S.

AU - Kari, L.

AU - Meric, C.

AU - Cadoz, M.

AU - Zahradnik, J.

AU - Starr, S.

AU - Plotkin, S.

PY - 2001/4/15

Y1 - 2001/4/15

N2 - The major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) is an important target of HLA-restricted cytotoxic T cells (CTL) after natural infection. A canarypox-CMV pp65 recombinant was studied for its ability to induce CMV pp65-specific CTL, helper T lymphocytes, and antibodies in a phase I clinical trial. Twenty-one CMV-seronegative adult volunteers were randomized to receive immunizations at months 0, 1, 3, and 6 with either canarypox-CMV pp65 or placebo. In canarypox-CMV pp65-immunized subjects, pp65-specific CTL were elicited after only 2 vaccinations and were present at months 12 and 26 in all subjects tested. Cell-depletion studies indicated that the CTL were phenotype CD8+. Peripheral blood mononuclear cells proliferated in response to stimulation with purified pp65, and antibodies specific for pp65 also were detected. Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV.

AB - The major matrix phosphoprotein 65 (pp65) of cytomegalovirus (CMV) is an important target of HLA-restricted cytotoxic T cells (CTL) after natural infection. A canarypox-CMV pp65 recombinant was studied for its ability to induce CMV pp65-specific CTL, helper T lymphocytes, and antibodies in a phase I clinical trial. Twenty-one CMV-seronegative adult volunteers were randomized to receive immunizations at months 0, 1, 3, and 6 with either canarypox-CMV pp65 or placebo. In canarypox-CMV pp65-immunized subjects, pp65-specific CTL were elicited after only 2 vaccinations and were present at months 12 and 26 in all subjects tested. Cell-depletion studies indicated that the CTL were phenotype CD8+. Peripheral blood mononuclear cells proliferated in response to stimulation with purified pp65, and antibodies specific for pp65 also were detected. Canarypox-CMV pp65 is the first recombinant vaccine to elicit CMV-specific CTL responses, which suggests the potential usefulness of this approach in preventing disease caused by CMV.

UR - http://www.scopus.com/inward/record.url?scp=0035871756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871756&partnerID=8YFLogxK

U2 - 10.1086/319680

DO - 10.1086/319680

M3 - Article

C2 - 11262198

AN - SCOPUS:0035871756

VL - 183

SP - 1171

EP - 1179

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 8

ER -